GlassScriptPhysician profile
Tak Shing Sak
NPI 1417388828
$5,789.96
in general payments reported to CMS, 2019-2025
22 companies · $2,012 in 2025
The $2,012 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $777 · 2022: $1,380 · 2023: $623 · 2024: $999 · 2025: $2,012.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,633.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,633.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,576.58 | 2021-2025 | |
| Novo Nordisk INC | $574.39 | 2021-2025 | Ozempic, Rybelsus |
| Madrigal Pharmaceuticals | $489.55 | 2024-2025 | Rezdiffra, Resmetirom |
| Gilead Sciences, INC. | $363.07 | 2024-2025 | Vemlidy |
| Ardelyx, INC. | $322.78 | 2024-2025 | Ibsrela |
| Ibsa Pharma INC. | $259.59 | 2021-2025 | Licart, Tirosint, Licart |
| Phathom Pharmaceuticals, INC. | $175.22 | 2024-2025 | Voquezna |
| Amarin Pharma, INC. | $132.34 | 2021-2022 | |
| Amgen INC. | $128.00 | 2021-2025 | Repatha, Otezla |
| Nestle Healthcare Nutrition INC. | $122.83 | 2021-2022 | |
| Esperion Therapeutics, INC. | $120.80 | 2025 | Nexletol |
| Scilex Pharmaceuticals INC. | $115.77 | 2024-2025 | |
| Lilly USA, LLC | $95.80 | 2022-2025 | Zepbound, Mounjaro |
| Insmed, INC. | $59.19 | 2025 | Brinsupri, Arikayce |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.57 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.45 | 2024-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $37.01 | 2021-2025 | Verquvo |
| Axsome Therapeutics, INC. | $27.33 | 2025 | Symbravo |
| Agepha Pharma Fz LLC | $26.74 | 2025 | Lodoco |
| Actelion Pharmaceuticals US, INC. | $23.44 | 2025 | Opsumit |
| Takeda Pharmaceuticals U.S.A., INC. | $19.65 | 2021 | |
| Viatris Specialty LLC | $18.86 | 2025 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tak Shing Sak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.